The publisher has been informed that there were errors in [Table 1] in the above article in Seminars in Thrombosis and Hemostasis, Volume 37, Number 6, 2011 (DOI: 10.1055/s-0031-1291382).
Table 1
Laboratory findings in Quebec platelet disorder
Laboratory test
|
Finding
|
Platelet count
|
Reduced or normal (80–245 × 109/L)
|
Other blood counts
|
Normal unless iron deficient
|
Platelet Function Analyzer-100® closure times
|
Normal
|
Bleeding time
|
Normal to mildly prolonged
|
Coagulation and fibrinolysis parameters
|
|
PT (INR)
|
Normal
|
aPTT
|
Normal
|
Fibrinogen
|
Normal
|
D-dimer
|
Normal
|
uPA
|
Normal in plasma prepared with platelet activation inhibitors
Elevated in platelets (∼400–600 ng uPA/109 platelets)
|
uPA-plasminogen activator inhibitor 1 complexes
|
Normal in plasma
Elevated in platelets
|
Plasmin- α2 plasmin inhibitor complexes
|
Normal in plasma
Elevated in platelets
|
Thromboelastography
(whole blood or platelet rich plasma)
|
Normal
|
Light transmission platelet aggregometry
|
Non-diagnostic findings
|
Epinephrine
|
Absent primary or absent secondary aggregation
|
Adenosine diphosphate
|
Normal to reduced
|
Collagen
|
Normal to reduced
|
Arachidonic acid
|
Normal
|
Thromboxane analogue U46619
|
Normal
|
Ristocetin
|
Normal
|
Platelet glycoprotein analysis
|
|
Western blot analysis for α-granule protein degradation and platelet uPA
|
α-granule protein degradation and increased platelet uPA
|
Plasma thrombopoietin levels
|
<31.3 pg/mL (reference interval: <31.3 pg/mL – 196 pg/mL)
|
Genetic tests for the QPD PLAU duplication mutation
|
Positive (duplicated and normal alleles detected)
|
Abbreviations: ADP, adenosine diphosphate; aPTT, activated partial thromboplastin time; PT (INR), prothrombin time (international normalized ratio); QPD, Quebec platelet disorder; uPA, urokinase plasminogen activator.
Note: The only correction in this table, as compared with the previous version, relates to plasma thrombopoietin levels. All other information is as per previously published. The entire table is provided here for completeness and ease of referral.
The plasma thrombopoietin (TPO) values and TPO assay reference interval that the authors were provided were incorrect. They apologize for not catching these errors before publication. Plasma TPO levels (determined with new samples and the same assay) are actually <31.3 pg/ml in QPD and most general population control samples.[1] A new version of [Table 1], with the correct information,[1] is included in this erratum. No other information in the authors' review requires correction.